An autologous cell therapy is, by definition, a different product every single time — manufactured from one specific patient’s cells, for that same patient. That’s the opposite of how pharmaceutical manufacturing normally works, and it shows in the cost and the turnaround time.
Most of the engineering effort on CLR-118 this year hasn’t gone into the CAR construct itself, which has been stable for a while now — it’s gone into closing the gap between our best manufacturing run and our average one.